Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECISION: Dose Ranging Trial of BTZ-043 in Combination With Bedaquiline and Delamanid in Pulmonary Tuberculosis
NCT05926466Phase 2Completed
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of BTZ-043 in pulmonary tuberculosis (TB). Started Sep 2023; status: completed.
02
Drugs
BTZ-043
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05926466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926466.